Edition:
United States

Valeant Pharmaceuticals International Inc (VRX)

VRX on New York Consolidated

10.82USD
27 Mar 2017
Change (% chg)

$0.07 (+0.69%)
Prev Close
$10.75
Open
$10.69
Day's High
$10.92
Day's Low
$10.66
Volume
2,506,576
Avg. Vol
18,120,868
52-wk High
$38.50
52-wk Low
$10.35

VRX

Chart for VRX

About

Valeant Pharmaceuticals International, Inc. is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment,... (more)

Overall

Beta: -0.13
Market Cap(Mil.): $3,662.63
Shares Outstanding(Mil.): 341.19
Dividend: --
Yield (%): --

Financials

  VRX Industry Sector
P/E (TTM): -- 29.17 29.94
EPS (TTM): -6.92 -- --
ROI: -5.78 13.48 13.01
ROE: -53.16 14.39 14.16

BRIEF-Valeant CEO's 2016 compensation was $62.7 mln

March 23 Valeant Pharmaceuticals International Inc:

Mar 23 2017

BRIEF-ValuAct reports open market purchse of 500,000 shares of Valeant Pharma

March 16 Valeant Pharmaceuticals International Inc

Mar 16 2017

BRIEF-Valeant Pharma CFO Paul Herendeen reports open market purchase of co's shares

March 16 Valeant Pharmaceuticals International Inc

Mar 16 2017

BRIEF-Valueact Holdings reports 5.2 pct stake in Valeant Pharma

March 16 Valeant Pharmaceuticals International Inc

Mar 16 2017

ValueAct raises its stake in Valeant Pharmaceuticals

March 16 Hedge fund ValueAct Holdings LP raised its stake to 5.2 percent in Valeant Pharmaceuticals International Inc, calling Valeant's shares "undervalued" and saying it intends to continue to discuss with the company to "enhance shareholder value".

Mar 16 2017

BRIEF-Glycyx Pharmaventures and Valeant agree to terms of licensing agreement in oncology

* Glycyx Pharmaventures and Valeant Pharmaceuticals agree to binding terms of licensing agreement in the field of oncology

Mar 15 2017

BRIEF-Valeant's Bausch + Lomb reports introduction of Biotrue Oneday

March 15 Valeant Pharmaceuticals International Inc:

Mar 15 2017

CANADA STOCKS-Futures indicate higher open as oil rebounds

March 15 Futures pointed to a higher opening for Canadian stocks on Wednesday as oil prices rebounded from three-month lows, a day after the S&P/TSX composite index tumbled to its lowest this year. March futures on the index were up 0.25 percent at 7:15 a.m. ET. The rebound in oil prices was due to a surprise drawdown in U.S. inventories and the International Energy Agency's figures suggesting OPEC cuts should push the crude market into deficit in time. The ma

Mar 15 2017

Ackman's Pershing Square sells Valeant stake, takes $3 billion loss

BOSTON Billionaire investor William Ackman walked away from Valeant Pharmaceuticals International Inc on Monday with a loss of more than $3 billion as he sold his entire stake in the struggling drug company after trying to rescue it for some 18 months. | Video

Mar 14 2017

Valeant shares fall as Ackman exit highlights company's challenges

BOSTON Valeant Pharmaceuticals Inc's stock price fell to its lowest level in eight years on Tuesday after the abrupt exit of its biggest supporter put renewed focus on the Canadian company's most pressing problem: raising capital to cut its roughly $30 billion debt pile. | Video

Mar 14 2017

More From Around the Web

Competitors

Earnings vs. Estimates